MY160699A - Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome - Google Patents

Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome

Info

Publication number
MY160699A
MY160699A MYPI2011000225A MYPI2011000225A MY160699A MY 160699 A MY160699 A MY 160699A MY PI2011000225 A MYPI2011000225 A MY PI2011000225A MY PI2011000225 A MYPI2011000225 A MY PI2011000225A MY 160699 A MY160699 A MY 160699A
Authority
MY
Malaysia
Prior art keywords
dengue
fever
infections
mediated
methods
Prior art date
Application number
MYPI2011000225A
Other languages
English (en)
Inventor
Neil M Bodie
Original Assignee
Trinity Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trinity Therapeutics Inc filed Critical Trinity Therapeutics Inc
Publication of MY160699A publication Critical patent/MY160699A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MYPI2011000225A 2008-07-18 2009-07-17 Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome MY160699A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8194308P 2008-07-18 2008-07-18

Publications (1)

Publication Number Publication Date
MY160699A true MY160699A (en) 2017-03-15

Family

ID=41551029

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2011000225A MY160699A (en) 2008-07-18 2009-07-17 Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome

Country Status (13)

Country Link
US (1) US8815813B2 (https=)
EP (1) EP2320924B1 (https=)
JP (1) JP5806112B2 (https=)
CN (1) CN102159231B (https=)
AU (2) AU2009270805B2 (https=)
BR (1) BRPI0915968B1 (https=)
CA (1) CA2731218A1 (https=)
HR (1) HRP20150620T1 (https=)
IL (1) IL210717A (https=)
MX (1) MX2011000647A (https=)
MY (1) MY160699A (https=)
SG (1) SG10201500597YA (https=)
WO (1) WO2010009380A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2559887C (en) 2004-03-10 2018-12-04 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subject
BRPI0915968B1 (pt) 2008-07-18 2021-11-23 Trinity Therapeutics, inc Uso de polipeptídeo purificado para tratar infecção pelo vírus da dengue
WO2016106342A2 (en) * 2014-12-22 2016-06-30 Middle Tennessee State University Methods for treating immune-mediated viral infections
US10227383B2 (en) * 2015-05-20 2019-03-12 Kagoshima University Specific modification of antibody with IgG-binding peptide
WO2017189891A1 (en) * 2016-04-27 2017-11-02 Middle Tennessee State University Methods for treating zika viral infections and associated complications
SG10202012408UA (en) 2016-06-13 2021-01-28 Univ Kagoshima SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE
CN115804362A (zh) * 2023-02-08 2023-03-17 中国医学科学院医学生物学研究所 一种IFN-α/βR-/-小鼠抗体依赖性增强感染的注射液及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189014A (en) * 1979-12-03 1993-02-23 Cowan Jr Fred M Method of treating cellular Fc receptor mediated hypersensitivity immune disorders
US4383317A (en) * 1980-10-30 1983-05-10 Bei Electronics, Inc. Shaft angle encoder having a circuit for synthesizing a skipped track output signal
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5693758A (en) * 1987-11-19 1997-12-02 501 Research Corporation Limited Immunoglobulin E competitor
US5932483A (en) * 1990-10-16 1999-08-03 Northwestern University Synthetic peptide and its uses
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6420127B1 (en) * 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
WO1997033603A1 (en) * 1996-03-13 1997-09-18 Trustees Of The University Of Pennsylvania Novel peptides which inhibit complement activation
ITMI962628A1 (it) 1996-12-16 1998-06-16 Tecnogen Scpa Composizione farmaceutica
WO2000015214A1 (en) * 1998-09-11 2000-03-23 Ilexus Pty Limited Fc RECEPTOR MODULATORS AND USES THEREOF
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
EP1121425B1 (en) * 1998-10-13 2005-06-29 The University Of Georgia Research Foundation, Inc. Stabilized bioactive peptides and methods of identification, synthesis and use
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
ATE368688T1 (de) 2000-11-08 2007-08-15 Fresenius Medical Care Affina Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
US6916904B2 (en) * 2002-04-24 2005-07-12 Zolaris Biosciences, Llc Inhibition of immune complex formation
US7351875B2 (en) 2002-06-07 2008-04-01 Trillium Therapeutics, Inc. FcγRIIa transgenic animal model for autoimmune disease
AU2002953533A0 (en) 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
CA2559887C (en) * 2004-03-10 2018-12-04 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subject
KR101380200B1 (ko) 2004-08-12 2014-04-01 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용하여 위장관계의 운동성을촉진하는 방법
EP1940436B1 (en) * 2005-09-06 2013-12-04 Trinity Therapeutics, Inc. Methods for treating immune mediated neurological diseases
WO2007068047A1 (en) 2005-12-13 2007-06-21 Trillium Therapeutics Inc Multimeric fc receptor polypeptides
US20120021988A1 (en) * 2007-08-14 2012-01-26 Bodie Neil M Methods for treating immune thrombocytopenia
BRPI0915968B1 (pt) 2008-07-18 2021-11-23 Trinity Therapeutics, inc Uso de polipeptídeo purificado para tratar infecção pelo vírus da dengue

Also Published As

Publication number Publication date
CN102159231A (zh) 2011-08-17
CA2731218A1 (en) 2010-01-21
AU2009270805A1 (en) 2010-01-21
IL210717A (en) 2017-07-31
CN102159231B (zh) 2016-06-15
JP5806112B2 (ja) 2015-11-10
WO2010009380A9 (en) 2010-04-08
BRPI0915968B1 (pt) 2021-11-23
BRPI0915968A2 (pt) 2020-08-18
US20110218157A1 (en) 2011-09-08
HRP20150620T1 (xx) 2015-09-25
EP2320924A4 (en) 2012-07-25
JP2011528665A (ja) 2011-11-24
IL210717A0 (en) 2011-03-31
US8815813B2 (en) 2014-08-26
AU2009270805B2 (en) 2016-11-03
SG10201500597YA (en) 2015-04-29
EP2320924A1 (en) 2011-05-18
EP2320924B1 (en) 2015-03-11
MX2011000647A (es) 2011-09-29
HK1158066A1 (en) 2012-07-13
WO2010009380A2 (en) 2010-01-21
AU2017200760A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
MY160699A (en) Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome
NZ616254A (en) Complexes of il-15 and il-15ralpha and uses thereof
EP4292659A3 (en) Antibodies that neutralize hepatitis b virus and uses thereof
CR20200467A (es) Agentes anticuerpos anti-cd25
MX2022014867A (es) Anticuerpos especificos del receptor de poliovirus humano (rvp).
PH12018500199A1 (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
EA202092417A1 (ru) Химерные рецепторы к dll3 и способы их применения
MX2019013033A (es) Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso.
EA201000471A1 (ru) Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин
PH12020550025A1 (en) Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
WO2009117030A3 (en) Improved compositions for the prevention and treatment of smallpox
AR105026A1 (es) ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
RU2015123476A (ru) Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения
FR2919804B1 (fr) Composition et vaccin therapeutique anti-tumoral
TR201815254T4 (tr) Tl1a'ya bağlanan anti̇korlar ve bunlarin kullanimlari
EA201591771A1 (ru) Человеческие антитела к белку f респираторного синцитиального вируса и способы их применения
MX2009012493A (es) Metodos de humanizacion de anticuerpo de conejo novedosos y anticuerpos de conejo humanizados.
PH12022550056A1 (en) Dll3-targeting antibodies and uses thereof
WO2006034292A3 (en) Antibodies against and methods for producing vaccines for respiratory syncytial virus
JP2013166763A5 (https=)
NZ720765A (en) Antibodies and methods of use
WO2014143343A8 (en) Hcv core lipid binding domain monoclonal antibodies
WO2013142300A3 (en) Jcv neutralizing antibodies
WO2005030806A3 (en) Norovirus monoclonal antibodies and peptides
Tsouchnikas et al. Immunization with immune complexes modulates the fine specificity of antibody responses to a flavivirus antigen